Feb 6 (Reuters) - Bausch + Lomb (BLCO.TO), opens new tab, will not be taken private at this time, the contact lens maker said on Thursday, sending its U.S.-listed shares down 7% to $16.50 in ...

After completing $300 billion in healthcare deals over several decades, there is one deal Bausch and Lomb (BLCO) chairman and CEO Brent Saunders won't be making in 2025. The one for his contact ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX ... portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic ...

As a fully integrated eye health business, Bausch + Lomb has an established line of contact lenses, intraocular lenses (“IOLs”) and other medical devices, surgical systems and devices ...

and Daily SiHy lenses and Bausch + Lomb ULTRA ® in our contact lens business. Surgical segment revenue was $231 million for the fourth quarter of 2024, as compared to $204 million for the fourth ...